Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$2.71 -2.2%	$3.07	$1.05 ▼ $3.97	$266.79M	1.92	630,070 shs	668,910 shs
ANNX Annexon	$2.45 +2.1%	$2.47	$1.28 ▼ $7.85	$268.80M	1.3	1.71 million shs	871,731 shs
TNXP Tonix Pharmaceuticals	$39.01 +3.5%	$38.84	$6.76 ▼ $130.00	$287M	1.7	1.36 million shs	1.27 million shs
VNRX VolitionRx	$0.64 -0.2%	$0.67	$0.40 ▼ $0.94	$66.55M	1.2	197,121 shs	137,752 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-17.50%	-2.87%	+87.54%	-18.62%
ANNX Annexon	0.00%	-2.39%	-17.09%	+24.37%	-61.78%
TNXP Tonix Pharmaceuticals	0.00%	-21.54%	+9.89%	+95.05%	-21.37%
VNRX VolitionRx	0.00%	-14.67%	-18.99%	+34.74%	-11.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.8388 of 5 stars	3.5	1.0	2.3	0.8	0.6
ANNX Annexon	2.2114 of 5 stars	3.5	1.0	1.9	2.5	0.6
TNXP Tonix Pharmaceuticals	3.4311 of 5 stars	3.5	3.0	3.8	3.3	0.6
VNRX VolitionRx	1.4611 of 5 stars	3.5	0.0	0.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	185.98% Upside
ANNX Annexon	3.00	Buy	$12.50	410.20% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$70.00	79.44% Upside
VNRX VolitionRx	3.00	Buy	$3.50	446.88% Upside

Current Analyst Ratings Breakdown

Latest VNRX, ADCT, ANNX, and TNXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/15/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/14/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $14.00
5/13/2025	ANNX Annexon	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $11.00

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	3.79	N/A	N/A	($2.10) per share	-1.29
ANNX Annexon	N/A	N/A	N/A	N/A	$2.75 per share	N/A
TNXP Tonix Pharmaceuticals	$10.09M	28.46	N/A	N/A	$31.82 per share	1.23
VNRX VolitionRx	$1.31M	50.86	N/A	N/A	($0.11) per share	-5.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
ANNX Annexon	-$138.20M	-$1.18	N/A	N/A	N/A	N/A	-54.45%	-46.56%	8/11/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$1,963.61	N/A	N/A	N/A	-1,313.87%	-120.96%	-101.28%	8/15/2025 (Estimated)
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest VNRX, ADCT, ANNX, and TNXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$6.71	N/A	N/A	N/A	$2.60 million	N/A
8/11/2025	Q2 2025	ANNX Annexon	-$0.36	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	N/A	N/A	N/A	$17.82 million	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/12/2025	Q1 2025	ANNX Annexon	-$0.30	-$0.37	-$0.07	-$0.37	N/A	N/A
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.46	4.16
ANNX Annexon	N/A	7.99	7.99
TNXP Tonix Pharmaceuticals	N/A	12.31	11.64
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
ANNX Annexon	N/A
TNXP Tonix Pharmaceuticals	82.26%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
ANNX Annexon	11.87%
TNXP Tonix Pharmaceuticals	0.03%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
ANNX Annexon	60	109.71 million	96.69 million	Optionable
TNXP Tonix Pharmaceuticals	50	7.36 million	7.36 million	Not Optionable
VNRX VolitionRx	80	103.98 million	80.80 million	Optionable

VNRX, ADCT, ANNX, and TNXP Headlines

Recent News About These Companies

VolitionRx (NYSE:VNRX) Given "Buy" Rating at D. Boral Capital

July 17, 2025 | marketbeat.com

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

July 16, 2025 | prnewswire.com

VolitionRx Limited (VNRX) - Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

July 8, 2025 | prnewswire.com

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

Jones Trading Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

June 11, 2025 | msn.com

VolitionRx director Guy Innes buys $10,772 in common stock

June 5, 2025 | investing.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

June 5, 2025 | insidertrades.com

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025 | prnewswire.com

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 15, 2025 | prnewswire.com

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 12, 2025 | prnewswire.com

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

May 7, 2025 | prnewswire.com

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

April 29, 2025 | prnewswire.com

VolitionRx enters new sales agreement, terminates old one

April 24, 2025 | investing.com

VolitionRx initiated with a Buy at H.C. Wainwright

April 8, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, ADCT, ANNX, and TNXP Company Descriptions

ADC Therapeutics NYSE:ADCT

$2.71 -0.06 (-2.17%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$2.87 +0.16 (+6.05%)

As of 08/1/2025 07:44 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Annexon NASDAQ:ANNX

$2.45 +0.05 (+2.08%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.58 +0.13 (+5.31%)

As of 08/1/2025 07:54 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Tonix Pharmaceuticals NASDAQ:TNXP

$39.01 +1.33 (+3.53%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$40.10 +1.09 (+2.79%)

As of 08/1/2025 07:59 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

VolitionRx NYSE:VNRX

$0.64 0.00 (-0.19%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.64 -0.01 (-0.78%)

As of 08/1/2025 06:59 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time